it is administered subcutaneously every 2 to 4 weeks, according to total ige values. however, few data are availableon adequate doses and period of treatment. patients with aserum ige levels between 70 and 300 iu/ml showed a good clinical response but biological markers are required to monitor the therapeutic effects. despite its safety omalizumab may cause from mild to moderate side effects, such as reactions at theinjection site (pain, swelling, itching and redness), headache and fever. rare, but more severe side effects are represented by sudden allergic reactions up to anaphylaxis